Renalytix Plc
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Renalytix Plc (LSE: RENX) develops artificial intelligence-enabled in vitro diagnostics for kidney disease, including its lead product kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed prognostic test assessing risk of rapid progressive decline in kidney function for adults with type 2 diabetes and chronic kidney disease stages 1-3b; the platform combines blood-based biomarkers, genetics, and electronic health record data to generate a low, moderate, or high risk score over five years, supporting clinical care, patient stratification for drug trials, drug target discovery, and transplant management; additional offerings include pharmaceutical services leveraging proprietary biomarker portfolios for chronic kidney disease research. Incorporated in 2018 and headquartered in London with primary operations in the United States focused on New York, Texas, Florida, and Arizona, the company targets healthcare providers, health systems, insurers, and pharmaceutical firms addressing the needs of over 14 million affected patients in the US. Recent developments include a September 2025 collaboration with Tempus AI to integrate kidneyintelX.dkd into precision medicine platforms for national US expansion; an August 2025 partnership with MVP Health Care providing access for 770,000 members in New York and Vermont; a £6.7 million oversubscribed equity fundraise in September 2025 to support Tempus integration and growth; collaborations with New York Kidney & Hypertension Medicine for community nephrology access to over 2,000 underserved patients and pharmaceutical services for clients including AstraZeneca; full electronic medical record integrations with New York primary care networks; and a planned ADS ratio change announced in November 2025, alongside Julian Baines transitioning to non-executive chairman effective January 2026.
Renalytix shares climb 24% as two-year kidney study data published
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
Renalytix first half revenues rise, but cautions pipeline is taking longer to convert
Renalytix shares fall 25% as revenues miss expectations
Renalytix expands US footprint with three new clinical partnerships
Renalytix (LON:RENX) Trading Down 1.7% – What’s Next?
Renalytix reports £4m balance sheet boost as notes convert
Renalytix upsized fundraise brings in £7m
Renalytix to raise £4.5m to support US expansion
Renalytix shares gain as billable test numbers set new company record
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
Renalytix Announces Financing with Expected Size of up to $4 Million
3 Ridiculously Enticing Stocks to Buy for Under a Buck
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024